Torres, AntoniMotos, AnaCilloniz, CatiaCeccato, AdrianFernandez-Barat, LaiaGabarrus, AlbertBermejo-Martin, JesusFerrer, RicardRiera, JordiPerez-Arnal, RaquelGarcia-Gasulla, DarioPeñuelas, OscarLorente, Josa Angelde Gonzalo-Calvo, DavidAlmansa, RaquelMenendez, RosarioPalomeque, AndreaVillar, Rosario AmayaAñon, Jose MBalan Mariño, AnaBarbera, CarmeBarberan, JoseBlandino Ortiz, AaronBoado, Maria VictoriaBustamante-Munguira, ElenaCaballero, JesusCanton-Bulnes, Maria LuisaCarbajales Perez, CristinaCarbonell, NievesCatalan-Gonzalez, Mercedesde Frutos, RaulFranco, NievesGalban, CristóbalGumucio-Sanguino, Víctor Dde la Torre, Maria Del CarmenDiaz, EmiliEstella, AngelGallego, ElenaGarcia Garmendia, Jose LuisGomez, Jose MHuerta, ArturoGarcia, Ruth Noemi JorgeLoza-Vazquez, AnaMarin-Corral, JudithMartin Delgado, Maria CruzMartinez de la Gandara, AmaliaMartinez Varela, IgnacioLopez Messa, JuanAlbaiceta, Guillermo MNieto, MaiteNovo, Mariana AndreaPeñasco, YhivianPerez-Garcia, FelipePozo-Laderas, Juan CarlosRicart, PilarSagredo, VictorSanchez-Miralles, AngelSancho Chinesta, SusanaSerra-Fortuny, MireiaSocias, LorenzoSole-Violan, JordiSuarez-Sipmann, FernandoTamayo Lomas, LuisTrenado, JoseUbeda, AlejandroValdivia, Luis JorgeVidal, PabloBarbe, Ferran2023-05-032023-05-032022-05-01Torres A, Motos A, Cillóniz C, Ceccato A, Fernández-Barat L, Gabarrús A, et al. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med. 2022 Jul;48(7):850-864.http://hdl.handle.net/10668/19575Although there is evidence supporting the benefits of corticosteroids in patients affected with severe coronavirus disease 2019 (COVID-19), there is little information related to their potential benefits or harm in some subgroups of patients admitted to the intensive care unit (ICU) with COVID-19. We aim to investigate to find candidate variables to guide personalized treatment with steroids in critically ill patients with COVID-19. Multicentre, observational cohort study including consecutive COVID-19 patients admitted to 55 Spanish ICUs. The primary outcome was 90-day mortality. Subsequent analyses in clinically relevant subgroups by age, ICU baseline illness severity, organ damage, laboratory findings and mechanical ventilation were performed. High doses of corticosteroids (≥ 12 mg/day equivalent dexamethasone dose), early administration of corticosteroid treatment ( Between February 2020 and October 2021, 4226 patients were included. Of these, 3592 (85%) patients had received systemic corticosteroids during hospitalisation. In the propensity-adjusted multivariable analysis, the use of corticosteroids was protective for 90-day mortality in the overall population (HR 0.77 [0.65-0.92], p = 0.003) and in-hospital mortality (SHR 0.70 [0.58-0.84], p  Corticosteroid in ICU-admitted patients with COVID-19 may be administered based on age, severity, baseline inflammation, and invasive mechanical ventilation. Early administration since symptom onset may prove harmful.enCOVID-19CorticosteroidsCritically illIntensive careAdrenal Cortex HormonesCritical IllnessHumansIntensive Care UnitsPrecision MedicineRespiration, ArtificialSteroidsCOVID-19 Drug Treatmentresearch article35727348open accessCorticoesteroidesEnfermedad críticaEsteroidesHumanosMedicina de precisiónRespiración artificialTratamiento farmacológico de COVID-19Unidades de cuidados intensivos10.1007/s00134-022-06726-w1432-1238PMC9211796https://link.springer.com/content/pdf/10.1007/s00134-022-06726-w.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211796/pdf